Evidence map›Paper›PMID 38939988›Full record

ArticleInfectious disorders drug targets2025

The Relationship between the Clinical Course of SARS-CoV-2 Infections and Expression of Bruton's Tyrosine Kinase.

Mitra Rezaei, Abdolreza Babamahmoodi, Alireza Mirahmadi, Niloufar Bineshfar, Shima Mahmoudi, Somayeh Ghadimi, Melika Valizadeh, Tannaz Malakouti, Fatemeh Talebian Taheri, Hadiseh Mohammadpour and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Infectious disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mitra RezaeiGenomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abdolreza BabamahmoodiGenomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Alireza MirahmadiGenomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Niloufar BineshfarGenomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shima MahmoudiPediatric Infectious Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Somayeh GhadimiGenomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Melika ValizadehGenomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Tannaz MalakoutiGenomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Fatemeh Talebian TaheriGenomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hadiseh MohammadpourDental Research Center, Dentistry Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Farinaz Nasr AzadaniGenomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Seyed Ali ZiaiDepartment of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Seyed Mohammad PoorhosseiniGenomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Majid MarjaniClinical Tuberculosis and Epidemiology Research Center, `National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBruton's Tyrosine Kinase (BTK), an important element for the production of several inflammatory cytokines, may play a role in the pathogenesis of COVID-19. This study aimed to assess BTK gene expression levels in COVID-19 cases based on disease severity and outcome.

methodsIn this study, 33 hospitalized patients with COVID-19 were recruited and divided into two groups based on the severity of the disease: "mild to moderate" and "severe to critical". A blood sample was taken from each patient, peripheral blood mononuclear cells (PBMCs) were extracted, and BTK gene expression was measured. The level of BTK gene expression was compared based on the demographic data, laboratory results, and the severity and outcome of the disease.

resultsAmong the 33 patients, 22 (66.7%) were male, with nearly half having at least one underlying condition. The severity groups comprised 12 patients in the "mild to moderate" category and 21 in the "severe to critical" category, with eight (24.2%) experiencing fatal outcomes. Age, weight, and BMI showed no significant associations with BTK expression. BTK expression was notably lower in "severe to critical" and ICU-admitted cases, as well as in individuals with low O2 saturation. However, no significant difference in BTK expression was observed between cured and deceased patients (p = 0.117).

conclusionBTK gene expression in PBMCs exhibited an inverse correlation with COVID- 19 severity. However, no difference was found between BTK expression and disease outcome.

Indexed as

Agammaglobulinaemia Tyrosine KinaseCOVID-19Leukocytes, MononuclearSARS-CoV-2Severity of Illness IndexAdultAgedFemaleHumansMaleMiddle AgedAgammaglobulinaemia Tyrosine KinaseBTK protein, humanBMI.Bruton’s Tyrosine KinaseCOVID-19gene expressionpotientsSARS-CoV-2

Identifiers

PMID38939988

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.